TY - JOUR
T1 - Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions
T2 - an update
AU - Aletaha, Daniel
AU - Kerschbaumer, Andreas
AU - Kastrati, Kastriot
AU - Dejaco, Christian
AU - Dougados, Maxime
AU - McInnes, Iain B.
AU - Sattar, Naveed
AU - Stamm, Tanja A.
AU - Takeuchi, Tsutomu
AU - Trauner, Michael
AU - Van Der Heijde, Désirée
AU - Voshaar, Marieke
AU - Winthrop, Kevin L.
AU - Ravelli, Angelo
AU - Betteridge, Neil
AU - Burmester, Gerd Rüdiger R.
AU - Bijlsma, Johannes W.J.
AU - Bykerk, Vivian
AU - Caporali, Roberto
AU - Choy, Ernest H.
AU - Codreanu, Catalin
AU - Combe, Bernard
AU - Crow, Mary K.
AU - De Wit, Maarten
AU - Emery, Paul
AU - Fleischmann, Roy M.
AU - Gabay, Cem
AU - Hetland, Merete Lund
AU - Hyrich, Kimme L.
AU - Iagnocco, Annamaria
AU - Isaacs, John D.
AU - Kremer, Joel M.
AU - Mariette, Xavier
AU - Merkel, Peter A.
AU - Mysler, Eduardo F.
AU - Nash, Peter
AU - Nurmohamed, Michael T.
AU - Pavelka, Karel
AU - Poor, Gyula
AU - Rubbert-Roth, Andrea
AU - Schulze-Koops, Hendrik
AU - Strangfeld, Anja
AU - Tanaka, Yoshiya
AU - Smolen, Josef S.
N1 - Funding Information:
This study was supported by Sanofi, (unrestricted grant).
Publisher Copyright:
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2023/6/1
Y1 - 2023/6/1
N2 - Background Targeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6Rα antibodies or by directly inhibiting the IL-6 cytokine. This paper is an update of a previous consensus document, based on most recent evidence and expert opinion, that aims to inform on the medical use of interfering with the IL-6 pathway. Methods A systematic literature research was performed that focused on IL-6-pathway inhibitors in inflammatory diseases. Evidence was put in context by a large group of international experts and patients in a subsequent consensus process. All were involved in formulating the consensus statements, and in the preparation of this document. Results The consensus process covered relevant aspects of dosing and populations for different indications of IL-6 pathway inhibitors that are approved across the world, including rheumatoid arthritis, polyarticular-course and systemic juvenile idiopathic arthritis, giant cell arteritis, Takayasu arteritis, adult-onset Still's disease, Castleman's disease, chimeric antigen receptor-T-cell-induced cytokine release syndrome, neuromyelitis optica spectrum disorder and severe COVID-19. Also addressed were other clinical aspects of the use of IL-6 pathway inhibitors, including pretreatment screening, safety, contraindications and monitoring. Conclusions The document provides a comprehensive consensus on the use of IL-6 inhibition to treat inflammatory disorders to inform healthcare professionals (including researchers), patients, administrators and payers.
AB - Background Targeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6Rα antibodies or by directly inhibiting the IL-6 cytokine. This paper is an update of a previous consensus document, based on most recent evidence and expert opinion, that aims to inform on the medical use of interfering with the IL-6 pathway. Methods A systematic literature research was performed that focused on IL-6-pathway inhibitors in inflammatory diseases. Evidence was put in context by a large group of international experts and patients in a subsequent consensus process. All were involved in formulating the consensus statements, and in the preparation of this document. Results The consensus process covered relevant aspects of dosing and populations for different indications of IL-6 pathway inhibitors that are approved across the world, including rheumatoid arthritis, polyarticular-course and systemic juvenile idiopathic arthritis, giant cell arteritis, Takayasu arteritis, adult-onset Still's disease, Castleman's disease, chimeric antigen receptor-T-cell-induced cytokine release syndrome, neuromyelitis optica spectrum disorder and severe COVID-19. Also addressed were other clinical aspects of the use of IL-6 pathway inhibitors, including pretreatment screening, safety, contraindications and monitoring. Conclusions The document provides a comprehensive consensus on the use of IL-6 inhibition to treat inflammatory disorders to inform healthcare professionals (including researchers), patients, administrators and payers.
KW - autoimmune diseases
KW - biological therapy
KW - rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=85136491534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136491534&partnerID=8YFLogxK
U2 - 10.1136/ard-2022-222784
DO - 10.1136/ard-2022-222784
M3 - Article
C2 - 35953263
AN - SCOPUS:85136491534
SN - 0003-4967
VL - 82
SP - 773
EP - 787
JO - Annals of the rheumatic diseases
JF - Annals of the rheumatic diseases
IS - 6
ER -